https://seekingalpha.com/news/4080088-jj-wins-fda-adcom-carvykti-label-expansion?source=feed_sector_healthcare
Mar 15, 2024 - FDA advisors unanimously voted to expand labeling for Carvykti, a CAR-T therapy developed by J&J (JNJ) and Legend Biotech (LEGN), for multiple myeloma. Read more here.
0
sa:-5134546788001620226
0
https://www.fool.com/investing/2024/03/15/the-smartest-dividend-stocks-to-buy-with-400-right/?source=iedfolrf0000001
Mar 15, 2024 - It's time to reward yourself with companies that treat their shareholders with steady and growing payouts.
0
fool:4905277460120251
0
https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446
Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
zc:-3282508303580057856
0
https://www.entrepreneur.com/es/marketing/esta-es-la-combinacion-de-seo-que-necesitas-para-vencer-al/471202
Mar 14, 2024 - Para obtener una presencia en línea que brinde resultados y altas clasificaciones a largo plazo, crea una estrategia que se centre en combinar las mejores prácticas de SEO y las directrices de E-A-T (Experiencia, Autoridad, Confianza) — aquí te decimos cómo.
0
ent:2200811751443357307
0
https://seekingalpha.com/article/4678163-jpst-good-short-term-income-fund-but-not-a-buy-at-these-levels?source=feed_tag_etf_portfolio_strategy
Mar 14, 2024 - JPMorgan Ultra-Short Income ETF is quite similar to T-bills, with slightly higher risk, and slightly higher returns. Read more on JPST ETF here.
0
sa:-7743243762114391803
0
https://www.zacks.com/stock/news/2240226/allogene-allo-inks-deal-with-arbor-bio-for-crispr-technology?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240226
Mar 13, 2024 - Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
zc:-2554321397242822348
0
https://www.entrepreneur.com/growing-a-business/heres-the-seo-combination-you-need-to-win-googles/469814
Mar 12, 2024 - For an online presence that delivers results and high rankings long term, create a strategy that focuses on combining SEO best practices and E-E-A-T guidelines — here's how.
0
ent:3234247060199767419
0
https://www.zacks.com/stock/news/2237533/what-makes-t-rowe-trow-a-new-strong-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2237533
Mar 07, 2024 - T. Rowe (TROW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zc:-941521460482778670
0
https://www.zacks.com/stock/news/2236364/w-t-wti-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2236364
Mar 05, 2024 - While the top- and bottom-line numbers for W&T (WTI) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zc:-7396144779111220938
0
https://www.zacks.com/stock/news/2236197/earnings-estimates-rising-for-t-rowe-trow-will-it-gain?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2236197
Mar 05, 2024 - T. Rowe (TROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zc:-4491410189173717542
0